Skip Navigation

European Heart Journal 1995 16(Supplement B):72-74; doi:10.1093/eurheartj/16.suppl_B.72
Copyright © 1995 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Besnier, J. M.
Right arrow Articles by Choutet, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Besnier, J. M.
Right arrow Articles by Choutet, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1995 The European Society of Cardiology

Medical treatment of infective endocarditis: General principles

J. M. Besnier and P. Choutet

Service de Maladies Infectieuses Hôpital Bretonneau Tours, France

Correspondence to: J. M. Besnier, Service de Maladies Infectieuses, Hôpital Bretonneau, 2 Bd Tonnellé, 37 044 Tours, France.

The main objective of medical treatment of infective endocarditis is to sterilize the vegetative lesions characteristic of the disease. The general principles of treatment are: (1) identification of the causative organism; (2) in vitro determination of its susceptibility, and (3) the choice of a bactericidal treatment. In vitro susceptibility, the minimum inhibitory concentration (MIC)/minimum bactericidal concentration (MBC) rate, the level of aminoglycoside resistance and in vitro synergy testing are determined according to the organism. Bactericidal therapy requires a combination of antimicrobials with synergistic activity, generally a cell-wall-active agent and an aminoglycoside. Treatment must be instituted parenterally, to ensure complete bioavailability, high serum concentrations and good penetration into the vegetations. The mode of administration depends on the organism, the serum-half-life and the mode of antimicrobial effect whether time or concentration-dependent, and the post-antibiotic effect (PAE). Cell-wall-active antibiotics (β-lactams and glycopeptides) with a time-dependent activity require concentrations above MIC for as long as possible between administrations, mainly if there is no PAE; conversely, aminoglycosides or fluoroquinolones with a concentration-dependent activity must be used to obtain a peak-concentration five to ten times the MIC. Therapy must be monitored rigorously. The clinical relevance of serum bactericidal titre is poor owing to lack of standardization and its poor predictive value of failure. The duration of therapy must be sufficient (4–6 weeks) to prevent failure or relapse.

Key Words: Infective endocarditis • antimicrobial


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.